MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases. Nanobodies® are proprietary therapeutic proteins based on single-domain antibody fragments, with the benefits of conventional antibodies but at 1/10th the size. MoonLake has licensed Merck KGaA’s phase 3-ready drug sonelokimab (M1095) […]
ResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung diseases. The company is building on research into how the microbiota influence lung diseases, carried out by company founder and Chief Scientific Officer C. Vivek Lal at University of Alabama at Birmingham. Chronic respiratory illness is associated with lung dysbiosis (abnormal lung microbiome) […]
Alchemab identifies naturally occurring protective antibodies that counter complex diseases, such as cancer and neurodegenerative diseases, by mining the antibody repertoires of individuals who are resistant to or recovered from disease. Alchemab’s approach was developed with support from scientific founders at Oxford University, Johns Hopkins University and Mount Sinai Hospital. The company’s approach starts by […]
Israel-based Wild Biotech is mining wild animal microbiomes for the discovery of novel human therapeutics, based on the “largest database ever assembled of the microbiome of wild animals”. Based on work published in Science, the company’s founders have sampled the faeces of 184 wild animals, including fish, birds, and mammals, from four different continents to […]
MUVON Therapeutics is spin-off from the University of Zurich developing an autologous cell therapy for the treatment of diseases related to skeletal muscle damage or degradation. The technology behind MUVON was developed over the past decade at the University of Zurich and in recent years has been funded by the EU under the Horizon 2020 […]
Founded in 2020, Chimerna Therapeutics has developed a platform for generating circular RNA, which overcomes the major limitations of RNA therapeutics, namely stability and abundance. The company says this proprietary technology makes robust endogenous expression of RNAs and RNA aptamers possible. By making RNA as a circle, rather than the normal linear form that predominates […]
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies, which it says overcome several of the major challenges with current degradation platforms, including oral bioavailability and CNS exposure. Founded in 2020 and based in Cambridge, UK, the company builds on work carried out in the Gunning Group at […]
SENISCA is a spinout company from the University of Exeter, founded in 2020 to develop new approaches to reverse cellular senescence (ageing) and treat diseases and aesthetic aspects of ageing. SENISCA says it has discovered a new and druggable means to reverse senescence through modulation of RNA splicing. The company’s founders have demonstrated that restoration […]
Delonix Bioworks is a Shanghai-based startup using synthetic biology to design bacteria to act as safer and more effective vaccines against bacterial infections and cancer. The Delonix team has developed a novel approach that builds on the established concept of live attenuated bacteria and combines it with the latest developments in synthetic biology. Delonix’s synthetic […]
Orna Therapeutics is an MIT spin-off developing fully engineered circular RNA (oRNA) therapeutics, a new class of RNA medicines with the potential to treat a wide range of diseases including cancer, autoimmune, and genetic disorders. Built on research from Prof. Daniel Anderson’s lab at MIT, oRNA is described by the company as the next revolution […]